$INTI
Inhibitor Therapeutics, Inc.

2014 Q4 Form 10-Q Financial Statement

#000119312514369132 Filed on October 10, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $590.0K $570.0K $240.0K
YoY Change 195.0% 137.5% 118.18%
% of Gross Profit
Research & Development $310.0K $167.0K $1.050M
YoY Change 1450.0% -84.1%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $900.0K $738.1K $1.292M
YoY Change 328.57% -42.89% 840.17%
Operating Profit -$738.1K -$1.292M
YoY Change -42.89% 840.17%
Interest Expense $0.00 $1.979K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$900.0K -$740.0K -$1.290M
YoY Change 309.09% -42.64% -301.56%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$900.0K -$740.1K -$1.292M
YoY Change 309.09% -42.74% -301.85%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 -$0.01 -$0.07
COMMON SHARES
Basic Shares Outstanding 211.4M shares 41.42M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $370.0K $380.0K $0.00
YoY Change -100.0%
Cash & Equivalents $365.2K $375.9K $112.00
Short-Term Investments
Other Short-Term Assets $97.82K $47.24K $0.00
YoY Change -100.0%
Inventory
Prepaid Expenses $97.82K
Receivables
Other Receivables
Total Short-Term Assets $463.0K $423.1K $112.00
YoY Change 4431.45% 377672.32% -99.99%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $463.0K $423.1K $112.00
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $463.0K $423.1K $112.00
YoY Change 4431.45% 377672.32% -99.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $325.0K $331.0K $233.3K
YoY Change 13.2% 41.88% 6.03%
Accrued Expenses $23.00K $10.00K $0.00
YoY Change -100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $40.00K $70.00K
YoY Change -100.0% -42.86%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $400.9K $432.6K $550.8K
YoY Change -48.34% -21.45% 37.69%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $400.9K $432.6K $550.8K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $400.9K $430.0K $550.8K
YoY Change -48.34% -21.93% -38.11%
SHAREHOLDERS EQUITY
Retained Earnings -$32.22M -$31.32M -$28.03M
YoY Change 14.07% 11.74%
Common Stock $32.29M $21.14K $1.889K
YoY Change 1709007.04% 1019.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $62.08K -$9.541K -$550.7K
YoY Change
Total Liabilities & Shareholders Equity $463.0K $423.1K $112.00
YoY Change 4431.45% 377672.32% -99.99%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$900.0K -$740.1K -$1.292M
YoY Change 309.09% -42.74% -301.85%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$520.0K -$380.0K -$120.0K
YoY Change 205.88% 216.67% -47.83%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 510.0K 490.0K 130.0K
YoY Change 200.0% 276.92%
NET CHANGE
Cash From Operating Activities -520.0K -380.0K -120.0K
Cash From Investing Activities
Cash From Financing Activities 510.0K 490.0K 130.0K
Net Change In Cash -10.00K 110.0K 10.00K
YoY Change 1000.0% -104.35%
FREE CASH FLOW
Cash From Operating Activities -$520.0K -$380.0K -$120.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
211419937 shares
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
211419937 shares
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9500000 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
31844187
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
330952
CY2014Q3 us-gaap Notes Payable Current
NotesPayableCurrent
41920
CY2014Q3 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
550000
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
432646
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
-9541
CY2014Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
6427
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31324870
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
21142
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
423105
CY2014Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
52500
CY2014Q3 us-gaap Interest Payable Current
InterestPayableCurrent
847
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q3 us-gaap Assets Current
AssetsCurrent
423105
CY2014Q3 us-gaap Assets
Assets
423105
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
375865
CY2014Q3 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
550000
CY2014Q3 us-gaap Other Assets Current
OtherAssetsCurrent
47240
CY2014Q3 hppi Common Stock Shares Forfeitable
CommonStockSharesForfeitable
20000000 shares
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
211419937 shares
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
857702
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18888971 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18888971 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9500000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
27479913
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
287072
CY2013Q4 us-gaap Notes Payable Current
NotesPayableCurrent
68428
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
776053
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-765836
CY2013Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
366130
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28247655
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
1889
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10217
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
52500
CY2013Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1923
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Assets Current
AssetsCurrent
10217
CY2013Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
10000
CY2013Q4 us-gaap Assets
Assets
10217
us-gaap Net Income Loss
NetIncomeLoss
-1619887
us-gaap Notes Issued1
NotesIssued1
152000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
619235
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
196588
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
217
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17620984 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1054178
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
us-gaap Revenues
Revenues
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-78733
us-gaap Debtor Reorganization Items Gain Loss On Settlement Of Other Claims Net1
DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet1
166676
us-gaap Operating Income Loss
OperatingIncomeLoss
-1786563
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-9087
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-857590
us-gaap Debtor Reorganization Items Other Expense Income
DebtorReorganizationItemsOtherExpenseIncome
117324
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1050004
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
196588
us-gaap Operating Expenses
OperatingExpenses
1786563
hppi Net Cash Provided By Operating Activities Before Reorganization Items
NetCashProvidedByOperatingActivitiesBeforeReorganizationItems
-530237
hppi Increase Decrease In Liabilities Subject To Compromise
IncreaseDecreaseInLiabilitiesSubjectToCompromise
-357265
hppi Deposit Reclassified To Preferred Stock
DepositReclassifiedToPreferredStock
30000
hppi In Process Research And Development Paid In Stock And Warrants
InProcessResearchAndDevelopmentPaidInStockAndWarrants
1020004
dei Trading Symbol
TradingSymbol
HPPI
dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001042418
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
56949513 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-784740
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <i>Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> </div>
us-gaap Revenues
Revenues
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
37240
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
63250
us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
619134
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
333882
us-gaap Operating Income Loss
OperatingIncomeLoss
-3040684
us-gaap Net Income Loss
NetIncomeLoss
-3077215
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
250000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
917914
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1160388
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
61307
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
375648
us-gaap Interest Expense
InterestExpense
36531
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
950000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2122770
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
273638
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
333882
us-gaap Operating Expenses
OperatingExpenses
3040684
hppi Issuance Of Preferred Stock
IssuanceOfPreferredStock
1290726
hppi Debt Instrument Interest Rate Accrual Percentage
DebtInstrumentInterestRateAccrualPercentage
0.18 pure
hppi Issuance Of Warrants In Connection With Debt
IssuanceOfWarrantsInConnectionWithDebt
450000
hppi Net Cash Provided By Operating Activities Before Reorganization Items
NetCashProvidedByOperatingActivitiesBeforeReorganizationItems
-784740
hppi Noncash Interest Expense
NoncashInterestExpense
24666
hppi Stock Issued During Period Value Debt Forgiveness
StockIssuedDuringPeriodValueDebtForgiveness
189768
CY2013Q3 us-gaap Revenues
Revenues
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1292439
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-1292439
hppi In Process Research And Development Paid In Stock And Warrants
InProcessResearchAndDevelopmentPaidInStockAndWarrants
1909860
hppi Issuance Of Common Stock For Common Stock Subscription Receivable
IssuanceOfCommonStockForCommonStockSubscriptionReceivable
1250000
hppi Collection Of Stock Subscription Receivable
CollectionOfStockSubscriptionReceivable
700000
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18888971 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
242435
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1050004
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
1292439
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
130115236 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Revenues
Revenues
us-gaap Operating Income Loss
OperatingIncomeLoss
-738090
us-gaap Net Income Loss
NetIncomeLoss
-740069
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
571127
us-gaap Interest Expense
InterestExpense
1979
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
166963
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
333882
us-gaap Operating Expenses
OperatingExpenses
738090

Files In Submission

Name View Source Status
0001193125-14-369132-index-headers.html Edgar Link pending
0001193125-14-369132-index.html Edgar Link pending
0001193125-14-369132.txt Edgar Link pending
0001193125-14-369132-xbrl.zip Edgar Link pending
d772477d10q.htm Edgar Link pending
d772477dex311.htm Edgar Link pending
d772477dex312.htm Edgar Link pending
d772477dex321.htm Edgar Link pending
d772477dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hppi-20140930.xml Edgar Link completed
hppi-20140930.xsd Edgar Link pending
hppi-20140930_cal.xml Edgar Link unprocessable
hppi-20140930_def.xml Edgar Link unprocessable
hppi-20140930_lab.xml Edgar Link unprocessable
hppi-20140930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending